drugset
drugset / Trial / NCT02010944

A Study to Compare How Much Solifenacin Succinate and Mirabegron Reach the Blood When Administered Together as Fixed-dose Combination Tablets and With Single Individual Tablets of the Same Medications at Three Dose Levels

NCT02010944 ↗

Phase 1 Completed 72 enrolled Astellas Pharma Europe B.V.
RandomizedCrossoverOpen-labelBasic science

Summary

This study compares the pharmacokinetics (PK), safety and tolerability of fixed dose combination (FDC) tablets containing solifenacin succinate and mirabegron with the co-administration of single entity tablets (SET), at three dose strengths.

Timeline

Start
2012-09
Primary completion
2012-11
Completion
2012-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Mirabegron Other / unclassified — Oral
Subject Solifenacin Small molecule — Oral

Indications

No indication recorded.